This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04171700
Recruitment Status : Terminated (The study was terminated due to a change in development priorities.)
First Posted : November 21, 2019
Results First Posted : October 2, 2023
Last Update Posted : October 2, 2023
Sponsor:
Information provided by (Responsible Party):
pharmaand GmbH

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: Rucaparib Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 83 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes
Actual Study Start Date : January 16, 2020
Actual Primary Completion Date : June 8, 2022
Actual Study Completion Date : July 15, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Rucaparib

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Rucaparib

Eligible participants will be enrolled in either Cohort A or Cohort B.

Cohort A: Up to 200 participants with deleterious mutations in BRCA1, BRCA2, PALB2, RAD51C or RAD51D.

Cohort B (Exploratory): Up to 20 participants with deleterious mutations in BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B.

 Drug: Rucaparib
Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).
Other Names:
  • Rubraca
  • Rucaparib camsylate
  • Rucaparib tablets
  • CO-338
  • PF 01367338
  • AG 014447


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Best Overall Response Rate by Investigator [ Time Frame: From first dose of study drug until disease progression (up to approximately 2 years) ]
    Best overall response rate as assessed by the investigator by RECIST v1.1 (or by RECIST v1.1 and PCWG3 in participants with advanced prostate cancer).


Secondary Outcome Measures :
  1. Overall Response Rate by Independent Radiology Review [ Time Frame: From first dose of study drug until disease progression (up to approximately 2 years) ]
    Best overall response rate by independent radiology review by RECIST v1.1 (or by RECIST v1.1 and PCWG3 in participants with advanced prostate cancer).

  2. Duration of Response [ Time Frame: From first dose of study drug until disease progression (up to approximately 2 years) ]
    Measure of clinical benefit, defined as the time from initial tumor response to documented tumor progression.

  3. Disease Control Rate [ Time Frame: From first dose of study drug until disease progression (up to approximately 2 years) ]
    Measure of clinical benefit, defined as the percentage of complete response (CR), partial response (PR), and stable disease (SD) beyond 16 weeks.

  4. Progression-free Survival [ Time Frame: From first dose of study drug until disease progression (up to approximately 2 years) ]
    Measure of clinical benefit, defined as the duration from study enrollment to objective tumor progression. Progression was defined using RECIST v1.1, as a 20% increase in the sum of diameters of target lesions (and an absolute increase of at least 5 mm), or unequivocal progression of existing non-target lesions, or the appearance of new lesions. For mCRPC disease, the PCWG3 confirmed bone disease progression criteria (2+2) were also incorporated.

  5. Overall Survival [ Time Frame: From first dose of study drug until disease progression (up to approximately 2 years) ]
    Measure of clinical benefit, defined as the duration from study enrollment to death.

  6. Number of Participants Experiencing Treatment-emergent Adverse Events [ Time Frame: From first dose of study drug until disease progression (up to approximately 2 years) ]
  7. Steady State Minimum Concentration [Cmin] [ Time Frame: From first dose of study drug until disease progression (up to approximately 2 years) ]
    Rucaparib pharmacokinetics


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Unresectable, locally advanced or metastatic solid tumor and relapsed/progressive disease
  • Measurable disease per RECIST v1.1 or modified RECIST v1.1 and PCWG3 (for prostate cancer)
  • Have a deleterious mutation (germline or somatic) in BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B. Note: Breast cancer patients that are HER2 negative and have germline BRCA1 or BRCA2 mutations AND patients with epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or metastatic castration-resistant prostate cancer with BRCA1 or BRCA2 mutations are ineligible for this trial.
  • At least one prior line of therapy extending overall survival or standard of care therapy for advanced disease. Note: Some tumor types have specific inclusion/exclusion criteria for previous treatments.
  • ECOG 0 or 1
  • Tumor tissue available for genomic analysis, or must be willing to have a biopsy if no archival tumor tissue available
  • Adequate organ function
  • Life expectancy of 4 months

Key Exclusion Criteria:

  • Active central nervous system brain metastases, leptomeningeal disease or primary tumor of CNS origin
  • Active second malignancy (Exceptions: Successfully treated malignancy with no active disease for 1 year, surgically cured and/or low-risk tumors, or patients receiving ongoing anticancer hormonal therapy for a previously treated cancer)
  • Pre-existing gastrointestinal disorders/conditions interfering with ingestion/absorption of rucaparib
  • Prior treatment with a PARP inhibitor
  • More than 3 prior lines of chemotherapy in the locally advanced/metastatic setting
  • History of myelodysplastic syndrome or acute myeloid leukemia
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04171700


Locations
Show Show 19 study locations
Sponsors and Collaborators
pharmaand GmbH
Investigators
Layout table for investigator information
Principal Investigator: Kim Reiss-Binder, MD University of Pennsylvania
  Study Documents (Full-Text)

Documents provided by pharmaand GmbH:
Study Protocol and Statistical Analysis Plan  [PDF] October 22, 2020

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: pharmaand GmbH
ClinicalTrials.gov Identifier: NCT04171700    
Other Study ID Numbers: CO-338-100
First Posted: November 21, 2019    Key Record Dates
Results First Posted: October 2, 2023
Last Update Posted: October 2, 2023
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

De-identified datasets for study results will be made available to qualified researchers in compliance with applicable privacy laws and data protection regulations.

Data will be provided by Clovis Oncology.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: Data will be made available to qualified researchers after the primary, secondary, and/or exploratory outcomes of the study are reported or published and for 1 year thereafter.
Access Criteria: Requests for de-identified datasets will be made available to qualified researchers following submission of a methodologically sound proposal to medinfo@clovisoncology.com.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by pharmaand GmbH:
rucaparib
PARPi
rare tumor
solid tumor
CO-338
ovarian cancer
prostate cancer
pancreatic cancer
breast cancer
lung cancer
colon cancer
gastric cancer
bladder cancer
colorectal cancer
PARP inhibitor
 homologous recombination
DNA repair
LODESTAR
germline
somatic
BRCA1
BRCA2
PALB2
RAD51C
RAD51D
BARD1
BRIP1
FANCA
RAD51
RAD51B
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Rucaparib
Poly(ADP-ribose) Polymerase Inhibitors
 Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents